Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age
group in a large US cohort with private insurance to detect potential decreases among …

Objectives. To detect decreases in anogenital warts (AGW) among sex and age groups
likely to be affected by human papillomavirus vaccination. Methods. We estimated annual …

Introduction This study aimed to evaluate the early population impact of Ontario's school-
based human papillomavirus (HPV) vaccination program, implemented in September 2007 …

Because of the rapid development of genital warts (GW) after infection, monitoring GW
trends may provide early evidence of population-level human papillomavirus (HPV) vaccine …

Background Human papillomavirus (HPV) vaccination remains underused in the United
States, and few population-level studies on effectiveness exist. Methods We examined …

Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human
papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the …

We examined the effectiveness of human papillomavirus vaccination by dose number and
spacing against incident genital warts in a cohort of 64,517 female health-plan enrollees in …

Background: Genital warts are caused by human papillomavirus (HPV); over 90% are due to
HPV types 6 and 11. We determined the percentage of persons who reported having been …

Background Assessing the impact and effectiveness of HPV vaccines on anogenital warts in
the United States can provide early indication of the success of vaccination programs as well …

Background Approximately 90% of genital warts are caused by human papillomavirus (HPV)
types 6 and 11. In the United States, HPV vaccination has been recommended for girls and …